Pfizer’s annual dividend yield stands at approximately 6.8%, one of the highest in the S&P 500 universe. With a market capitalization of roughly $144 billion, the company generates sufficient free cash flow to cover its current payout, and CEO Albert Bourla has described the dividend as a “sacred cow.” At this yield, a hypothetical $12 000 allocation would deliver about $820 in annual dividends, representing a reliable income stream for patient investors despite the stock’s muted price performance over the past five years.

Investors are keenly focused on the Phase 2b Vesper-2 and Vesper-3 trials for MET-097i, an obesity and type 2 diabetes asset acquired through Pfizer’s November 2025 Metsera deal valued at up to $10 billion. Positive data from these studies, expected in early 2026, could significantly bolster sentiment. Additionally, last month’s GLP-1 licensing agreement with YaoPharma, carrying potential milestone and royalty payments of up to $2.1 billion, underscores management’s commitment to expanding in the fast-growing receptor agonist market, projected by Grand View Research to reach over $200 billion by 2033.

For fiscal 2026, Pfizer forecasts revenue of $59.5 billion to $62.5 billion, with adjusted EPS guidance centered roughly 5.7% below 2025’s midpoint. Management attributes this shortfall to an anticipated $1.5 billion decline in COVID-19 product sales and another $1.5 billion from loss of exclusivity on key brands. Blockbuster Eliquis is scheduled to lose patent protection in 2026 (with generics expected by 2028), followed by Ibrance and Xtandi in 2027, creating headwinds that underscore the importance of pipeline success for near-term upside potential.